0001599298-24-000006.txt : 20240104
0001599298-24-000006.hdr.sgml : 20240104
20240104161645
ACCESSION NUMBER: 0001599298-24-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DUGGAN ROBERT W
CENTRAL INDEX KEY: 0001055919
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 24512130
MAIL ADDRESS:
STREET 1: 611 SOUTH FORT HARRISON AVE
STREET 2: SUITE 306
CITY: CLEARWATER
STATE: FL
ZIP: 33756
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wk-form4_1704402965.xml
FORM 4
X0508
4
2024-01-02
0
0001599298
Summit Therapeutics Inc.
SMMT
0001055919
DUGGAN ROBERT W
C/O SUMMIT THERAPEUTICS INC.
2882 SAND HILL ROAD, SUITE 106
MENLO PARK
CA
94025
1
1
1
0
Co-Chief Executive Officer
0
Stock Option (right to buy)
2.64
2024-01-02
4
A
0
74545
1.32
A
2034-01-02
Common Stock
74545
74545
D
The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.
The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400.
/s/ Ankur Dhingra, as Attorney-in-Fact for Robert W. Duggan
2024-01-04